Published: August 1, 2025

(For eligible participants, study-related treatments, medical exams, and follow-ups during the study period are fully covered/funded by the respective research teams.)

1. Open-Label, Single-Center Phase I Trial of NY-ESO-1 Antigen-Specific High-Affinity TCR-Transduced Autologous T Cells (Super1 TCR-T) for NY-ESO-1-Positive Advanced Solid Tumors

● Patient Population: Solid tumors (NY-ESO-1-positive advanced solid tumors)

● Principal Investigator (PI): Zhang Xing

● Contact Information:

○Prof. Zhang Xing: Mon PM, Wed & Thu AM (Yuexiu Campus)

○Prof. Peng Ruiqing: Thu PM (Yuexiu Campus)

○Prof. Pan Qiuzhong: Wed PM (Huangpu Campus)

2. Phase II Trial of Neoadjuvant Chemotherapy + Camrelizumab for Thoracic Esophageal Squamous Cell Carcinoma with Cervical Lymph Node Metastasis

● Patient Population: Esophageal cancer (thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis)

● Principal Investigator (PI): Zhang Xu

● Contact: Assistant Su, Tel: +86-13640843744

3. Phase II Trial of Neoadjuvant Chemotherapy + Camrelizumab for Elderly Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

● Patient Population: Esophageal cancer (elderly patients with locally advanced esophageal squamous cell carcinoma)

● Principal Investigator (PI): Zhang Xu

● Contact: Assistant Su, Tel: +86-13640843744

4. Phase I Trial of EBV mRNA Vaccine (WGc-043 Injection) in EBV-Positive Relapsed or Refractory Lymphoma: Safety, Tolerability, PK, Immunogenicity, and Preliminary Anti-Tumor Activity

● Patient Population: EBV-positive relapsed/refractory lymphoma

● Principal Investigator (PI): Cai Qingqing

● Contact: Assistant Yang, Tel: +86-18826275445

5. Phase 3, Randomized, Double-Blind, Multicenter Study of SONROTOCLAX + Zanubrutinib vs. Placebo + Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

● Patient Population: Relapsed/refractory mantle cell lymphoma

● Principal Investigator (PI): Cai Qingqing

● Contact: Assistant Yang, Tel: +86-18826275445

6. SOUNDTRACK-B: Modular, Single-Arm, Multicenter, Open-Label Phase II Study of AZD0486 in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

● Patient Population: Relapsed/refractory B-cell non-Hodgkin’s lymphoma

● Principal Investigator (PI): Cai Qingqing

● Contact: Assistant Yang, Tel: +86-18826275445

Note:

For detailed inclusion/exclusion criteria or full outpatient schedules, please visit the official SYSUCC Patient Recruitment System or contact the

designated research assistants.

For more recruitment information, visit: http://www.sysucc.org.cn/node/10932